Current Issue

Volume 38 - No. 4 - 2021
Editorial

 


Dear readers,


The virtual WC11 is behind us, but a new series of congress­es focusing on microphysiological systems (MPS) has gained initial funding and sponsors and is shifting into top gear in planning the first MPS World Summit to be held on May 30-June 3, 2022 as a hybrid event in New Orleans, Louisi­ana. A second, free pre-event focusing on systems engineer­ing of MPS will take place virtually on December 9, 2021. The organizers are now calling for abstracts for the pre-event and for further sponsors of the first summit. Find out more on https://mpsworldsummit.com.


The pathogenesis of COVID-19 in animals is different to that in humans, even in genetically modified mice expressing the human ACE2 receptor. This issue’s Food for Thought … con­tribution by Ian Kang and colleagues argues that human in vitro microphysiological systems have already contributed important insights into the disease, for example, on its neuro­pathogenesis, and are suitable and relevant models to answer further pressing open research questions on COVID-19.


Sandra Verstraelen et al. describe a pilot study to assess the acute inhalation toxicity of vapors of petroleum substances and their constituents based on measurement of a selection of endpoints after exposure of an alveolar epithelial cell line at the air-liquid interface. They find that the measured toxicity is consistent with data from previous in vivo experiments in animals and humans, indicating that the in vitro model can be used to predict in vivo toxicity.


Gianluca Selvestrel and colleagues present a software appli­cation that can support the safety evaluation assessment of cosmetic products. It can assess the ingredients of a potential cosmetic product based on existing experimental data or on the in silico values predicted by its integrated software. Then it considers these in relation to the concentration they will have, the product type they are to be used in, and the result­ing expected exposure to determine if the product would pose regulatory concerns.


As adverse outcome pathways (AOPs) for manufactured nanomaterials are still lacking, Sivakumar Murugadoss and colleagues search the literature to identify potential molec­ular initiating events (MIE) or early key events (KE) of ex­isting AOPs, which were originally developed for chemicals, that appear to also be triggered by nanomaterials. Based on two case studies they demonstrate how in vitro strategies can be used to test and verify such potential MIE/KEs to link nanomaterials to AOPs.


Awareness on quality control issues in in vitro research is increasing. Julia Tigges et al. show how to put general rec­ommendations on quality control into practice to charac­terize master cell banks and working cell banks of human induced pluripotent stem cells in an academic research envi­ronment. They argue that the moderate investment is worth­while when considering the implications of discovering that one has been working with a cell line that is not or no longer what it should be.


Pesticide regulation currently requires high numbers of ex­perimental animals although many pesticides fall into groups with structural similarities. Wanda van der Stel et al. present their strategy of using an AOP to determine relevant in vitro methods that can feed and support read-across to assess the neurological hazard of the members of pesticide classes. The two case studies they describe may be adapted to guide the assessment of other chemical classes.


Miaoying Shi et al. combine in vitro data from electrophys­iological assays in cardiomyocytes and transport assays in intestinal cells to predict human in vivo cardiotoxicity upon oral exposure to two herbal alkaloids that are used as anti-ad­diction drugs. They use reverse dosimetry based on physi­ologically based kinetic modeling to compare their predic­tions with published human in vivo data.


The ban on animal testing for cosmetic ingredients that came into force in the EU in 2013 was celebrated as a break­through for the 3Rs and was widely supported by consum­ers and cosmetics companies. However, this ban conflicts with the REACH regulation, which demands toxicity data for chemicals produced or imported into the EU independent of intended use. Jean Knight and colleagues investigate how many chemicals intended to be used only as cosmetic ingre­dients have undergone animal testing for REACH purposes since the 2013 ban and call for resolution of the conflict be­tween the two regulations.


The first defined approaches for animal-free skin sensiti­zation testing have recently been published as OECD Test Guideline 497. Andreas Natsch and colleagues use the skin sensitization data collected in the many different assays on many different chemicals to illustrate that the human in vitro data predicts the human in vivo data from skin patch assays better than the animal in vivo data does. They conclude that animal in vivo data should not be used as the sole reference data for the validation of in vitro assays.


A letter by Paul Locke and colleagues informs on the goals of the Humane Research and Testing Act that was recently introduced in the US House of Representatives. The Corners bring you up to date with recent international developments in 3Rs organizations. Take a look at our online events calen­dar at www.altex.org to start planning for 2022.


With this last issue of 2021, we thank this year’s authors and reviewers as well as our subscribers, readers, members, and sponsors for supporting ALTEX. We wish you a happy holiday season.


 


 


Sonja von Aulock and the ALTEX Edition Editorial Office with Franz P. Gruber and the Board of ALTEX Edition

[read more]
Food for Thought ...

COVID-19 – prime time for microphysiological systems, as illustrated for the brain

Vol. 38 No. 4 (2021), pp. 535-549
https://doi.org/10.14573/altex.2110131
Abstract
Articles

An in vitro air-liquid interface inhalation platform for petroleum substances and constituents

Vol. 38 No. 4 (2021), pp. 550-564
https://doi.org/10.14573/altex.2010211
Abstract

SpheraCosmolife: a new tool for the risk assessment of cosmetic products

Vol. 38 No. 4 (2021), pp. 565-579
https://doi.org/10.14573/altex.2010221
Abstract

A strategy towards the generation of testable adverse outcome pathways for nanomaterials

Vol. 38 No. 4 (2021), pp. 580-594
https://doi.org/10.14573/altex.2102191
Abstract

Academic application of Good Cell Culture Practice for induced pluripotent stem cells

Vol. 38 No. 4 (2021), pp. 595-614
https://doi.org/10.14573/altex.2101221
Abstract

New approach methods (NAMs) supporting read-across: Two neurotoxicity AOP-based IATA case studies

Vol. 38 No. 4 (2021), pp. 615-635
https://doi.org/10.14573/altex.2103051
Abstract

A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans

Vol. 38 No. 4 (2021), pp. 636-652
https://doi.org/10.14573/altex.2103311
Abstract

Continuing animal tests on cosmetic ingredients for REACH in the EU

Vol. 38 No. 4 (2021), pp. 653-668
https://doi.org/10.14573/altex.2104221
Abstract

A triangular approach for the validation of new approach methods for skin sensitization

Vol. 38 No. 4 (2021), pp. 669-677
https://doi.org/10.14573/altex.2105111
Abstract
Corners
empty image

Corners

Vol. 38 No. 4 (2021), pp. 681-690
Editorial Material
empty image

Imprint

Vol. 38 No. 4 (2021), pp. 691
empty image

Cover

Vol. 38 No. 4 (2021), pp. U1-U4